AngioDynamics Stock Price, Forecast & Analysis (NASDAQ:ANGO)

AngioDynamics trades on the NASDAQ under the ticker symbol "ANGO."

AngioDynamics, Inc. (NASDAQ:ANGO) released its quarterly earnings results on Thursday, October, 3rd. The medical instruments supplier reported $0.08 earnings per share for the quarter, beating analysts' consensus estimates of $0.04 by $0.04. The medical instruments supplier had revenue of $66 million for the quarter, compared to analyst estimates of $67.74 million. AngioDynamics had a net margin of 17.79% and a return on equity of 4.89%. The firm's revenue was up 3.3% on a year-over-year basis. During the same period last year, the firm earned $0.16 earnings per share. View AngioDynamics' Earnings History.

AngioDynamics is scheduled to release their next quarterly earnings announcement on Friday, January 3rd 2020. View Earnings Estimates for AngioDynamics.

AngioDynamics issued an update on its FY20 earnings guidance on Thursday, October, 3rd. The company provided earnings per share (EPS) guidance of $0.10-0.15 for the period, compared to the Thomson Reuters consensus EPS estimate of $0.26. The company issued revenue guidance of $280-286 million, compared to the consensus revenue estimate of $281.89 million.

2 equities research analysts have issued twelve-month price objectives for AngioDynamics' stock. Their forecasts range from $21.00 to $23.00. On average, they expect AngioDynamics' stock price to reach $22.00 in the next twelve months. This suggests a possible upside of 44.2% from the stock's current price. View Analyst Price Targets for AngioDynamics.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AngioDynamics in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for AngioDynamics.

Headlines about ANGO stock have trended somewhat negative on Friday, InfoTrie Sentiment reports. InfoTrie identifies negative and positive press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. AngioDynamics earned a coverage optimism score of -1.4 on InfoTrie's scale. They also assigned news stories about the medical instruments supplier a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the near term. View News Stories for AngioDynamics.

AngioDynamics saw a drop in short interest during the month of October. As of October 31st, there was short interest totalling 748,500 shares, a drop of 7.9% from the September 30th total of 812,500 shares. Based on an average daily trading volume, of 267,200 shares, the short-interest ratio is presently 2.8 days. Currently, 2.0% of the shares of the stock are sold short. View AngioDynamics' Current Options Chain.

Some companies that are related to AngioDynamics include Abbott Laboratories (ABT), Medtronic (MDT), Stryker (SYK), Becton Dickinson and (BDX), Intuitive Surgical (ISRG), Boston Scientific (BSX), Edwards Lifesciences (EW), Baxter International (BAX), IDEXX Laboratories (IDXX), ResMed (RMD), DexCom (DXCM), Teleflex (TFX), Steris (STE), Hologic (HOLX) and Varian Medical Systems (VAR).

Based on aggregate information from My MarketBeat watchlists, some companies that other AngioDynamics investors own include Oasis Petroleum (OAS), Intel (INTC), General Electric (GE), Mattel (MAT), Chesapeake Energy (CHK), Centurylink (CTL), DIGITAL RLTY TR/SH (DLR), Hanesbrands (HBI), Kimco Realty (KIM) and Regions Financial (RF).

AngioDynamics' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Tributary Capital Management LLC (1.80%), Fenimore Asset Management Inc. (1.52%), Systematic Financial Management LP (1.09%), Foundry Partners LLC (0.65%), State of New Jersey Common Pension Fund D (0.40%) and Rhumbline Advisers (0.32%). Company insiders that own AngioDynamics stock include James C Clemmer, Kevin J Gould and Michael Greiner. View Institutional Ownership Trends for AngioDynamics.

ANGO stock was sold by a variety of institutional investors in the last quarter, including Tributary Capital Management LLC, Foundry Partners LLC, Keybank National Association OH, Municipal Employees Retirement System of Michigan, Brinker Capital Inc., Strs Ohio, First National Bank of Omaha and Hancock Whitney Corp. View Insider Buying and Selling for AngioDynamics.

ANGO stock was purchased by a variety of institutional investors in the last quarter, including State of New Jersey Common Pension Fund D, Mackay Shields LLC, Assenagon Asset Management S.A., Boston Advisors LLC, Systematic Financial Management LP, Tibra Equities Europe Ltd, Meeder Asset Management Inc. and State of Alaska Department of Revenue. View Insider Buying and Selling for AngioDynamics.

Shares of ANGO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ANGO stock can currently be purchased for approximately $15.26.

AngioDynamics has a market capitalization of $574.08 million and generates $359.48 million in revenue each year. The medical instruments supplier earns $61.34 million in net income (profit) each year or $0.83 on an earnings per share basis. AngioDynamics employs 1,050 workers across the globe.View Additional Information About AngioDynamics.

The official website for AngioDynamics is http://www.angiodynamics.com/.

AngioDynamics' mailing address is 14 PLAZA DRIVE, LATHAM NY, 12110. The medical instruments supplier can be reached via phone at 518-795-1400 or via email at [email protected]